Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-01-07 Fusidic acid
| Sodium fusidate |
|
Formulary
|
Tablets 250mg **RAG under consultation and awaiting update - Please use local/national antimicrobial guidelines to support prescribing choices. ** |
 MHRA: Systemic fusidic acid and interaction with statins |
|
| Sodium fusidate injection |
|
Formulary
|
Infusion 500mg On advice of Microbiology only. |
|
MHRA: Systemic fusidic acid and interaction with statins |
|
Links
Blackpool Teaching Hospitals: Antimicrobial Formulary- British Association for Sexual Health and HIV
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Lancashire and South Cumbria Critical Care - Vancomycin Guideline
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- LSCMMG prescribing information sheet: Colistimethate For Nebulisation in Adult Patients with Non-Cystic Fibrosis Bronchiectasis
- LSCMMG: Colistimethate for nebulisation (Colomycin®) - Prescribing Information Sheet
- LSCMMG: Fidaxomicin
- LSCMMG: Linezolid
- LSCMMG: Linezolid Prescriber Information Sheet
- LSCMMG: Oritavancin
- LSCMMG: Rifaximin
- MHRA Drug safety update Sept 2011: Systemic fusidic acid and interaction with statins
- MHRA: Colobreathe: risk of capsule breakage—new instructions for use
- MHRA: Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions
- MHRA: Prescribing medicines in renal impairment: using the appropriate estimate of renal function to avoid the risk of adverse drug reactions
- MHRA: Systemic fusidic acid and interaction with statins
- MHRA: Systemic fusidic acid and interaction with statins
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE ESUOM25: Non-cystic fibrosis bronchiectasis: colistimethate sodium
- NICE evidence summary: Rifaximin for pouchitis
- NICE NG110: Prostatitis (acute): antimicrobial prescribing
- NICE NG111: Pyelonephritis (acute): antimicrobial prescribing
- NICE NG114: Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing
- NICE NG117: Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing
- NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing
- NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing
- NICE NG152: Leg ulcer infection: antimicrobial prescribing
- NICE NG153: Impetigo: antimicrobial prescribing
- NICE NG182: Insect bites and stings: antimicrobial prescribing
- NICE NG184: Human and animal bites: antimicrobial prescribing
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG190: Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG198: Acne vulgaris: management
- NICE NG199: Clostridioides difficile infection: antimicrobial prescribing
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG50: Cirrhosis in over 16s: assessment and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE NG79: Sinusitis (acute): antimicrobial prescribing
- NICE NG84: Sore throat (acute): antimicrobial prescribing
- NICE NG91: Otitis media (acute): antimicrobial prescribing
- NICE NG95: Lyme disease
- NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
- NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
- NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
- NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
- PHE: management and treatment of Clostridium difficile infection May 2013
- UHMB IV Vancomycin administration and monitoring guidelines
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023